2. Signaling Pathways
  3. Protein Tyrosine Kinase/RTK
  4. Syk

Syk

Spleen tyrosine kinase

Syk

Related Products

PDF 0.56 MB

Syk (Spleen tyrosine kinase) is a cytosolic non-receptor protein tyrosine kinase (PTK) that is expressed at high levels, both in hematopoietic cells (such as mast cells, B lymphocytes, T lymphocytes, neutrophils, dendritic cells, and macrophages) and in non-hematopoietic cells.

Syk mediates key signal transduction pathways following the activation of immune cell receptors. Syk associates with different receptors on the surface of various cells such as B cells, mast cells, monocytes, macrophages, and neutrophils, and even osteoclasts and breast cancer cells. Following the engagement of these receptors with their ligands, SYK is activated and orchestrates diverse cellular responses, including cytokine production (in T cells and monocytes) and phagocytosis (in macrophages).

Syk Related Products (61):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-12067
    R406
    		Inhibitor 98.72%
    R406 is an orally available and competitive Syk/FLT3 inhibitor for ATP binding with a Ki of 30 nM, potently inhibits Syk kinase activity in vitro with an IC50 of 41 nM, measured at an ATP concentration corresponding to its Km value. R406 reduces immune complex-mediated inflammation. R406 also inhibits Lyn (IC50=63 nM) and Lck (IC50=37 nM).
    R406
  • HY-13038A
    Fostamatinib
    		Inhibitor 99.50%
    Fostamatinib (R788) is the oral proagent of the active compound R406. R406 is an orally available and competitive Syk/FLT3 inhibitor with a Ki of 30 nM and an IC50 of 41 nM. R406 also inhibits Lyn (IC50=63 nM) and Lck (IC50=37 nM).
    Fostamatinib
  • HY-13518
    Piceatannol
    		Inhibitor 98.90%
    Piceatannol is a well-known Syk inhibitor and reduces the expression of iNOS induced by TNF. Piceatannol is an effective agent for research of acute lung injury (ALI). Piceatannol is a naturally occurring polyphenolic stilbene found in various fruits and vegetables and exhibits anticancer and anti-inflammatory properties. Piceatannol induces apoptosis in DLBCL cell lines. Piceatannol induces autophagy and apoptosis in MOLT-4 human leukemia cells.
    Piceatannol
  • HY-15968
    Entospletinib
    		Inhibitor 99.88%
    Entospletinib (GS-9973) is an orally bioavailable, selective Syk inhibitor with an IC50 of 7.7 nM.
    Entospletinib
  • HY-15323
    PRT062607 Hydrochloride
    		Inhibitor 98.07%
    PRT062607 (P505-15) Hydrochloride is an orally available Syk inhibitor (IC50: 1 nM) that inhibits inflammation and induction Apoptosis. PRT062607 Hydrochloride exerts potent antitumor activity in tumor xenograft mouse models.
    PRT062607 Hydrochloride
  • HY-76474A
    BAY 61-3606 hydrochloride
    		Inhibitor 98.98%
    BAY 61-3606 hydrochloride is an orally available, ATP-competitive, reversible and highly selective Syk inhibitor with a Ki of 7.5 nM and an IC50 of 10 nM . BAY 61-3606 hydrochloride reduces ERK1/2 and Akt phosphorylation in neuroblastoma cell. BAY 61-3606 hydrochloride induces a large decrease of Syk phosphorylation in K-rn cell lysates. BAY 61-3606 hydrochloride sensitizes TRAIL-induced apoptosis by downregulating Mcl-1 in breast cancer cells.
    BAY 61-3606 hydrochloride
  • HY-124146
    BI1002494
    		Inhibitor
    BI1002494 is an orally active, potent, and selective spleen tyrosine kinase (SYK) inhibitor. BI 1002494 exhibits an IC50 of 115 nM in inhibiting high-affinity IgE receptor-mediated mast cell and basophil degranulation. BI1002494 can be utilized in immunology reesearch.
    BI1002494
  • HY-123625
    R-348 choline
    		Inhibitor
    R-348 (R-932348) choline is a potent and orally active JAK3 and Syk inhibitor. R-348 reduces IFN-γ, IL-6, and IL-10 expression. R-348 effectively diminishes acute cardiac allograft rejection.
    R-348 choline
  • HY-15999
    Cerdulatinib
    		Inhibitor 99.06%
    Cerdulatinib (PRT062070) is a selective Tyk2 inhibitor with an IC50 of 0.5 nM. Cerdulatinib (PRT062070) also is a dual JAK and SYK inhibitor with IC50s of 12, 6, 8 and 32 for JAK1, 2, 3 and SYK, respectively.
    Cerdulatinib
  • HY-11108
    R406 free base
    		Inhibitor 99.80%
    R406 free base is an orally available and competitive Syk/FLT3 inhibitor for ATP binding with a Ki of 30 nM, potently inhibits Syk kinase activity in vitro with an IC50 of 41 nM, measured at an ATP concentration corresponding to its Km value. R406 free base reduces immune complex-mediated inflammation. R406 free base also inhibits Lyn (IC50=63 nM) and Lck (IC50=37 nM).
    R406 free base
  • HY-14985
    BAY 61-3606 dihydrochloride
    		Inhibitor 99.91%
    BAY 61-3606 dihydrochloride is an orally available, ATP-competitive, reversible and highly selective Syk inhibitor with a Ki of 7.5 nM an IC50 of 10 nM. BAY 61-3606 dihydrochloride reduces ERK1/2 and Akt phosphorylation in neuroblastoma cell. BAY 61-3606 dihydrochloride induces a large decrease of Syk phosphorylation in K-rn cell lysates. Bay 61-3606 dihydrochloride sensitizes TRAIL-induced apoptosis by downregulating Mcl-1 in breast cancer cells.
    BAY 61-3606 dihydrochloride
  • HY-13038
    Fostamatinib Disodium
    		Inhibitor 99.88%
    Fostamatinib Disodium (R788 Disodium) is the oral proagent of the active compound R406. R406 is an orally available and competitive Syk/FLT3 inhibitor with a Ki of 30 nM and an IC50 of 41 nM. R406 also inhibits Lyn (IC50=63 nM) and Lck (IC50=37 nM).
    Fostamatinib Disodium
  • HY-109091
    Lanraplenib
    		Inhibitor 99.12%
    Lanraplenib (GS-9876) is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib (GS-9876) inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans.
    Lanraplenib
  • HY-78263
    MNS
    		Inhibitor 99.55%
    MNS (NSC 170724), the beta-nitrostyrene derivative, is a potent tyrosine kinase inhibitor and a broad-spectrum antiplatelet agent. MNS completely inhibits U46619, ADP-, arachidonic acid-, collagen-, and thrombin-induced platelet aggregation with IC50 values of 2.1, 4.1, 5.8, 7.0, and 12.7 μM, respectively. MNS inhibits Src, Syk, and FAK with IC50 of 27.3, 2.8, and 97.6 μM, respectively.
    MNS
  • HY-103018
    Gusacitinib
    		Inhibitor 99.41%
    Gusacitinib (ASN-002) is an orally active dual SYK/JAK kinase inhibitor with IC50 values of 5, 46, 4, 11 and 8 nM for SYK, JAK1, JAK2, JAK3 and TYK2, respectively. Gusacitinib rapidly and significantly suppressed key inflammatory pathways implicated in atopic dermatitis pathogenesis. Gusacitinib can be used in the research of chronic hand eczema and cancers such as basal cell carcinoma.
    Gusacitinib
  • HY-12974
    PRT-060318
    		Inhibitor 99.04%
    PRT-060318 (PRT318) is a novel selective inhibitor of the tyrosine kinase Syk with an IC50 of 4 nM.
    PRT-060318
  • HY-13038B
    Fostamatinib disodium hexahydrate
    		Inhibitor 99.73%
    Fostamatinib (R788) disodium hexahydrate is the oral proagent of the active compound R406. R406 is an orally available and competitive Syk/FLT3 inhibitor with a Ki of 30 nM and an IC50 of 41 nM. R406 also inhibits Lyn (IC50=63 nM) and Lck (IC50=37 nM).
    Fostamatinib disodium hexahydrate
  • HY-112390A
    Syk Inhibitor II
    		Inhibitor 98.05%
    Syk Inhibitor II is a potent, high selective and ATP-competitive Syk inhibitor with an IC50 of 41 nM. Syk Inhibitor II inhibits 5-HT release from RBL-cells with an IC50 of 460 nM. Syk Inhibitor II shows less potent against other kinases and has anti-allergic effect.
    Syk Inhibitor II
  • HY-100867A
    Mivavotinib monohydrochloride
    		Inhibitor 99.91%
    TAK-659 hydrochloride is a highly potent, selective, reversible and orally available dual inhibitor of spleen tyrosine kinase (SYK) and fms related tyrosine kinase 3 (FLT3), with an IC50 of 3.2 nM and 4.6 nM for SYK and FLT3, respectively. TAK-659 hydrochloride induces cell death in tumor cells but not in nontumor cells, and with potential for the treatment of chronic lymphocytic leukemia (CLL).
    Mivavotinib monohydrochloride
  • HY-15322
    PRT062607
    		Inhibitor
    PRT062607(P505-15; PRT-2607; BIIB-057) is a highly specific and potent inhibitor of Syk with IC50 of 1-2 nM; >80-fold selective for Syk than Fgr, Lyn, FAK, Pyk2 and Zap70.
    PRT062607